Axxcess Wealth Management LLC Boosts Stake in Pfizer Inc. $PFE

Axxcess Wealth Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 27.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 203,514 shares of the biopharmaceutical company’s stock after purchasing an additional 43,296 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Pfizer were worth $5,186,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in PFE. Fiduciary Alliance LLC boosted its holdings in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Pfizer in the third quarter worth about $3,019,000. Vista Investment Partners LLC grew its position in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Money Concepts Capital Corp raised its stake in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its holdings in Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $27.41 on Thursday. The company has a market cap of $155.82 billion, a PE ratio of 20.15 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The stock’s 50 day simple moving average is $25.91 and its two-hundred day simple moving average is $25.28. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the company posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PFE shares. Zacks Research lowered shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Citigroup assumed coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.